Crinetics Pharmaceuticals, Inc. (CRNX)
Healthcare · NMS
Price as at 30 Sept 2026, 17:19 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Crinetics Pharmaceuticals, Inc. trades at $84.95, which is 60% above the $33.56 our fair value estimate puts on the business. On that measure it screens as expensive, which is not the same as saying it will fall.
Our moat model scores it 24 out of 100, which is little in the way of a moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
CRNX earnings and analyst estimates
Recommendation mix, 14 published ratings
Estimates are the published analyst consensus and move often. An earnings date is scheduled, not certain, and a share tends to reprice most violently on the day itself.
About Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and cushing's disease; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease; and SST3 Agonist program for the treatment of polycystic kidney disease, as well as Oral GLP-1 and Oral GIP nonpeptides for the treatment of obesity. The company has an agreement with Sanwa Kagaku Kenkyusho Co., Ltd to develop and commercialize Paltusotine in Japan, and Cellular Longevity, Inc. to develop and commercialize CRN01941, a somatostatin receptor type 2 agonist. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
CRNX passes 2 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Super investor ownership
7 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Farallon Capital, FARALLON CAPITAL MANAGEMENT, L.L.C.$336.37M · 1.6% of book
- Marshall Wace, MARSHALL WACE, LLP$42.16M · 0.0% of book
- Ken Fisher, Fisher Asset Management, LLC$27.75M · 0.0% of book
- Impax Asset Management, Impax Asset Management Group plc$16.28M · 0.1% of book
- Ken Griffin, CITADEL ADVISORS LLC$5.18M · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Politician trades in CRNX
Trades in CRNX disclosed by members of Congress and executive-branch officials, latest first:
- Gilbert Cisneros · HouseSell · $15,001 - $50,000 · traded 30 Jul 2026 · disclosed 4 Sept 2026
- Gilbert Cisneros · HouseBuy · $1,001 - $15,000 · traded 3 Mar 2026 · disclosed 7 Apr 2026
- Gilbert Cisneros · HouseBuy · $1,001 - $15,000 · traded 17 Apr 2025 · disclosed 6 May 2025
- Gilbert Cisneros · HouseBuy · $1,001 - $15,000 · traded 29 Jan 2025 · disclosed 11 Feb 2025
A disclosure reports a value band, not an amount, and is due up to 45 days after the trade; some arrive later. Every filer we track, each with their own page, is on the Congress trading tracker.
CRNX peers
The largest companies in the same industry (Biotechnology), then in the same sector.
- CSLLY CSL Limited
- RVMD Revolution Medicines, Inc.
- CMXHF CSL Limited
- ALNY Alnylam Pharmaceuticals, Inc.
- RPRX Royalty Pharma plc
- INCY Incyte Corporation
- INSM Insmed Incorporated
- GNMSF Genmab A/S
Every healthcare company we cover is on the Healthcare hub.
Common questions
Is Crinetics Pharmaceuticals, Inc. (CRNX) undervalued?
Against our fair value estimate of $33.56, CRNX at $84.95 is 60% above fair value. That is one model's answer, not a recommendation. It is built from normalized earning power with growth capped deliberately low, which understates companies whose value is mostly future growth.
Which funds own CRNX?
7 of the institutions we track reported a position in CRNX in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
Where does SteadyShares get its CRNX data?
Fundamentals for CRNX come from company filings and exchange data, as listed on NMS; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 17:19 UTC and is delayed. Our data quality score for this company is 83/100, which is the share of the inputs behind our scores that were actually available rather than assumed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for CRNX, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.